洋葱伯克霍尔德菌的氟喹诺酮耐药突变体
Fluoroquinolone-resistant mutants of Burkholderia cepacia.
作者信息
Pope C F, Gillespie S H, Pratten J R, McHugh T D
机构信息
Centre for Medical Microbiology, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom.
出版信息
Antimicrob Agents Chemother. 2008 Mar;52(3):1201-3. doi: 10.1128/AAC.00799-07. Epub 2007 Dec 26.
Abstract
Fluoroquinolone-resistant Burkholderia cepacia mutants were selected on ciprofloxacin. The rate of mutation in gyrA was estimated to be 9.6 x 10(-11) mutations per division. Mutations in gyrA conferred 12- to 64-fold increases in MIC, and an additional parC mutation conferred a large increase in MIC (>256-fold). Growth rate, biofilm formation, and survival in water and during drying were not impaired in strains containing single gyrA mutations. Double mutants were impaired only in growth rate (0.85, relative to the susceptible parent).
摘要
在环丙沙星上筛选出对氟喹诺酮耐药的洋葱伯克霍尔德菌突变体。gyrA基因的突变率估计为每代9.6×10⁻¹¹个突变。gyrA基因突变使最低抑菌浓度（MIC）增加了12至64倍，而额外的parC基因突变使MIC大幅增加（>256倍）。含有单个gyrA基因突变的菌株在生长速率、生物膜形成以及在水中和干燥过程中的存活率方面均未受损。双突变体仅在生长速率方面受到影响（相对于敏感亲本为0.85）。
相似文献
1
Fluoroquinolone-resistant mutants of Burkholderia cepacia.
Antimicrob Agents Chemother. 2008 Mar;52(3):1201-3. doi: 10.1128/AAC.00799-07. Epub 2007 Dec 26.
2
Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Microb Drug Resist. 2003 Spring;9(1):17-24. doi: 10.1089/107662903764736300.
3
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004.
4
The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
J Antimicrob Chemother. 2006 Oct;58(4):733-40. doi: 10.1093/jac/dkl333. Epub 2006 Aug 8.
5
Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Int J Antimicrob Agents. 2005 Apr;25(4):290-5. doi: 10.1016/j.ijantimicag.2004.11.012.
6
Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
J Microbiol. 2005 Oct;43(5):391-7.
7
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
J Antimicrob Chemother. 2009 May;63(5):886-94. doi: 10.1093/jac/dkp057. Epub 2009 Mar 11.
8
Characterization of the mechanisms of fluoroquinolone resistance in vancomycin-resistant enterococci of different origins.
J Chemother. 2011 Apr;23(2):87-91. doi: 10.1179/joc.2011.23.2.87.
9
Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
Int J Antimicrob Agents. 2010 Jan;35(1):76-9. doi: 10.1016/j.ijantimicag.2009.08.003. Epub 2009 Sep 24.
10
Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
Antimicrob Agents Chemother. 2004 Aug;48(8):3024-7. doi: 10.1128/AAC.48.8.3024-3027.2004.
引用本文的文献
1
The fitness connection of antibiotic resistance.
Front Microbiol. 2025 Apr 10;16:1556656. doi: 10.3389/fmicb.2025.1556656. eCollection 2025.
2
Multicenter Investigation of Drug-Resistance in Burkholderia Cepacia Bloodstream Infections in Hebei Province, China, from 2016 to 2021.
Infect Drug Resist. 2024 May 3;17:1731-1739. doi: 10.2147/IDR.S457314. eCollection 2024.
3
Development of Live Attenuated Typhimurium Vaccine Strain Using Radiation Mutation Enhancement Technology (R-MET).
Front Immunol. 2022 Jul 11;13:931052. doi: 10.3389/fimmu.2022.931052. eCollection 2022.
4
Bacterial defenses against a natural antibiotic promote collateral resilience to clinical antibiotics.
PLoS Biol. 2021 Mar 10;19(3):e3001093. doi: 10.1371/journal.pbio.3001093. eCollection 2021 Mar.
5
Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.
Expert Rev Anti Infect Ther. 2018 Feb;16(2):89-110. doi: 10.1080/14787210.2018.1425139. Epub 2018 Jan 16.
6
Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria.
Front Microbiol. 2017 Nov 16;8:2261. doi: 10.3389/fmicb.2017.02261. eCollection 2017.
7
Highly Diversified Population during Chronic Colonization in Cystic Fibrosis.
Front Microbiol. 2017 Oct 6;8:1892. doi: 10.3389/fmicb.2017.01892. eCollection 2017.
8
Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches.
Front Microbiol. 2017 Aug 22;8:1592. doi: 10.3389/fmicb.2017.01592. eCollection 2017.
9
Antibiotic resistance in Burkholderia species.
Drug Resist Updat. 2016 Sep;28:82-90. doi: 10.1016/j.drup.2016.07.003. Epub 2016 Jul 30.
10
The contribution of antibiotic resistance mechanisms in clinical Burkholderia cepacia complex isolates: an emphasis on efflux pump activity.
PLoS One. 2014 Aug 25;9(8):e104986. doi: 10.1371/journal.pone.0104986. eCollection 2014.
本文引用的文献
1
Mutations of Bacteria from Virus Sensitivity to Virus Resistance.
Genetics. 1943 Nov;28(6):491-511. doi: 10.1093/genetics/28.6.491.
2
A METHOD FOR THE DETERMINATION OF THE RATE OF GROWTH OF TUBERCLE BACILLI BY THE USE OF SMALL INOCULA.
J Bacteriol. 1949 Aug;58(2):247-55. doi: 10.1128/jb.58.2.247-255.1949.
3
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Clin Microbiol Infect. 2005 Sep;11(9):750-8. doi: 10.1111/j.1469-0691.2005.01211.x.
4
Rifampicin resistance in tuberculosis outbreak, London, England.
Emerg Infect Dis. 2005 Jun;11(6):931-4. doi: 10.3201/eid1106.041262.
5
Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates.
J Antimicrob Chemother. 2005 Aug;56(2):344-8. doi: 10.1093/jac/dki191. Epub 2005 Jun 14.
6
Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa.
J Antimicrob Chemother. 2005 Jan;55(1):22-30. doi: 10.1093/jac/dkh505. Epub 2004 Dec 1.
7
Molecular mechanisms of fluoroquinolone resistance.
J Microbiol Immunol Infect. 2003 Mar;36(1):1-9.
8
Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Microb Drug Resist. 2003 Spring;9(1):17-24. doi: 10.1089/107662903764736300.
9
Fluoroquinolones: action and resistance.
Curr Top Med Chem. 2003;3(3):249-82. doi: 10.2174/1568026033452537.
10
Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants.
J Antimicrob Chemother. 2002 Nov;50(5):657-64. doi: 10.1093/jac/dkf185.
Zotero 插件